Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant700 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,395 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03478358 | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05507593 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04525638 | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | unknown | Phase 2 | 30 | Fundación de investigación HMOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05451134 | Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma | unknown | — | 300 | China National Center for Cardiovascular DiseasesOTHER_GOV | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05027100 | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | unknown | N/A | 33 | Haibo ZhangOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03741517 | Biomarker Study of Pancreatic Neuroendocrine Tumours | unknown | — | 40 | Uppsala UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05320458 | Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer | unknown | N/A | 11 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02817945 | Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | unknown | Phase 2 | 192 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05299255 | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05268952 | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0) | unknown | N/A | 100 | University Hospital, AntwerpOTHER | 2 | Mar 7, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05245994 | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | unknown | Phase 2 | 60 | Li Zhang, MDOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04890444 | China Adrenal Disease Registry(CASE) | unknown | — | 2,000 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02446704 | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 66 | Zofia PiotrowskaOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05191849 | Circulating EV Long RNA Profiles in SCLC | unknown | N/A | 60 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05158491 | Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC | unknown | Phase 1 / Phase 2 | 63 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04901754 | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer(CAMERA) | unknown | Phase 2 | 38 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05113355 | Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm | unknown | Phase 2 | 23 | Peking Union Medical College HospitalOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05076786 | Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04927611 | Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm | unknown | — | 200 | Fudan UniversityOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT04947774 | Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer | unknown | — | 100 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04427787 | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET(LOLA) | unknown | Phase 2 | 69 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05034133 | Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 20 | Beijing Haidian HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05001412 | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC | unknown | Phase 1 | 36 | Zhou ChengzhiOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04985201 | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04698941 | Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 29, 2021 | clinicaltrials |
| NCT04951557 | Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas | unknown | — | 5,000 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04933175 | Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer | unknown | Phase 2 | 50 | Liu ZhenhuaOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT04931446 | Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis | unknown | — | 200 | Xian-Jun YuOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02823691 | The MetNET-2 Trial(MetNET-2) | unknown | Early Phase 1 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT04890795 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 237 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT04891081 | Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease | unknown | — | 50 | University Medical Centre LjubljanaOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04331912 | PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment | unknown | — | 100 | University of Warmia and MazuryOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT02990780 | Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC | unknown | Phase 3 | 266 | Shanghai Chest HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04863456 | Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement | unknown | N/A | 90 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 28, 2021 | clinicaltrials |
| NCT02695459 | Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin | unknown | Phase 2 | 39 | The Netherlands Cancer InstituteOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT04790539 | a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 71 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT04790708 | Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)(FENET-2016) | unknown | N/A | 250 | University Hospital of FerraraOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT04790955 | Effect of Combination Therapy on SCLC After Initial Treatment Failure | unknown | — | 48 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT04782089 | Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer | unknown | N/A | 20 | Qilu Hospital of Shandong UniversityOTHER | 0 | Mar 4, 2021 | clinicaltrials |
| NCT04691063 | The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. | unknown | Phase 3 | 486 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04390802 | A Pilot Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Pituitary Adenomas | unknown | — | 40 | Massachusetts General HospitalOTHER | 0 | Feb 24, 2021 | clinicaltrials |
| NCT04760171 | Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis | unknown | — | 10 | The Leeds Teaching Hospitals NHS TrustOTHER | 0 | Feb 18, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 31, 2022source: clinicaltrials